Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00768755 · ClinicalTrials.gov registry record · Phase 1
Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer
A Phase 1 study of Carcinoma, Non-Small Cell Lung, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT00768755: Completed Phase 1 study of Carcinoma, Non-Small Cell Lung, sponsored by Pfizer.
NCT00768755 is a Phase 1 study of Carcinoma, Non-Small Cell Lung that has completed, run by Pfizer. The registered enrollment target is 180 participants, below the 322-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00768755, a Phase 1 study of Carcinoma, Non-Small Cell Lung, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
AG-013736 (axitinib) in combination with cisplatin and pemetrexed will be evaluated as first-line treatment of patients with locally advanced, recurrent, or metastatic non-squamous, non small cell lung cancer (NSCLC).
Primary Outcome
Time in months from the date of randomization to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus minus the date of randomization plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]); death was determined from AE data (where the outcome was "Death") or from the end of study data.
Conditions Studied
Interventions
- DRUG axitinib
- DRUG chemotherapy
Study Locations (20)
Other
- Pfizer Investigational Site - Genova
- Pfizer Investigational Site - Lido Di Camaiore (LU)
- Pfizer Investigational Site - Orbassano (TO)
- Pfizer Investigational Site - Lubin
- Pfizer Investigational Site - Otwock
- Pfizer Investigational Site - Piła
- Pfizer Investigational Site - Poznan
Georgia
- Pfizer Investigational Site - Atlanta
- Pfizer Investigational Site - Decatur
- Pfizer Investigational Site - Macon
- Pfizer Investigational Site - Marietta
- Pfizer Investigational Site - Sandy Springs
Illinois
- Pfizer Investigational Site - Bloomington
- Pfizer Investigational Site - Peoria
Pennsylvania
- Pfizer Investigational Site - Hershey
- Pfizer Investigational Site - West Reading
Rhode Island
- Pfizer Investigational Site - East Providence
- Pfizer Investigational Site - East Providence
Alabama
- Pfizer Investigational Site - Huntsville
Shizuoka
- Pfizer Investigational Site - Sunto-gun
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2009-01 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
What the finished NCT00768755 record still lists
NCT00768755 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 322-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (44% lower).
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 2 interventions - of which axitinib is the first listed.
NCT00768755 names 20 study sites across 7 states, led by Other, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT00768755 about?
NCT00768755 is a clinical study titled "Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer". AG-013736 (axitinib) in combination with cisplatin and pemetrexed will be evaluated as first-line treatment of patients with locally advanced, recurrent, or metastatic non-squamous, non small cell lung cancer (NSCLC).
What is the current status of trial NCT00768755?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2009-01. Estimated completion is 2012-03.
What conditions does trial NCT00768755 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT00768755?
The interventions under investigation include: axitinib (DRUG), chemotherapy (DRUG).
Who is sponsoring clinical trial NCT00768755?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00768755 being conducted?
This trial has 20 study locations across Alabama, Georgia, Illinois, Pennsylvania, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00768755's enrollment target sits among peer trials
180 53rd of 130 higher than 78 of 130 other Carcinoma, Non-Small Cell Lung trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
RECRUITING · Phase 1
-
A Study of LY4175408 in Participants With Advanced Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia